Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Trop Med Int Health ; 4(12): 801-11, 1999 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10632987

RESUMEN

Two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana were treated with two leishmanicidal drugs (pentamidine and allopurinol) combined with recombinant interferon-gamma restoring Th-1 favouring conditions in the patients. Parasites decreased dramatically in the lesions and macrophages diminished concomitantly, while IL-12-producing Langerhans cells and interferon-gamma- producing NK and CD8 + lymphocytes increased in a reciprocal manner. The CD4+/CD8 + ratio in the peripheral blood normalized. During exogenous administration of interferon-gamma the parasites' capacity to inhibit the oxidative burst of the patients' monocytes was abolished. Even though Th-1-favouring conditions were restored, both patients relapsed two months after therapy was discontinued. We conclude that the tendency to develop a disease-promoting Th-2 response in DCL patients is unaffected by, and independent of, parasite numbers. Even though intensive treatment in DCL patients induced Th-1 disease restricting conditions, the disease-promoting immunomodulation of few persistent Leishmania sufficed to revert the immune response.


Asunto(s)
Antiprotozoarios/uso terapéutico , Interferón gamma/uso terapéutico , Células de Langerhans/efectos de los fármacos , Leishmania mexicana , Leishmaniasis Cutánea Difusa/tratamiento farmacológico , Leishmaniasis Cutánea Difusa/inmunología , Pentamidina/uso terapéutico , Alopurinol/uso terapéutico , Animales , Antimetabolitos/uso terapéutico , Relación CD4-CD8/efectos de los fármacos , Quimioterapia Combinada , Humanos , Células Asesinas Naturales/efectos de los fármacos , Células Asesinas Naturales/inmunología , Células de Langerhans/inmunología , Células de Langerhans/parasitología , Leishmaniasis Cutánea Difusa/patología , Proteínas Recombinantes , Estallido Respiratorio/efectos de los fármacos , Estallido Respiratorio/inmunología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA